<DOC>
	<DOC>NCT02856269</DOC>
	<brief_summary>The purpose of this pilot study is to determine whether zinc supplementation significantly affects immune activation in HIV-infected subjects.</brief_summary>
	<brief_title>Zinc Supplementation and Cardiovascular Risk in HIV</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>HIV1 infection Age ≥18 years Zinc level ≤0.75 mg/L Receiving a stable antiretroviral regimen with no plans to change during study Documentation of an HIV1 RNA level of ≤400 copies/mL No diarrhea or nausea/vomiting for the last month Pregnancy/lactation Presence of inflammatory condition Regular use of agents that may affect inflammation in the last 3 months. The regular use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable for the last 3 months and is not expected to change during the study. Presence of active neoplastic diseases requiring chemotherapy and/or use of immunosuppressive drugs Known cardiovascular disease Uncontrolled diabetes Allergy or intolerance to zinc sulfate. AST and ALT &gt; 2.5 x ULN Hemoglobin &lt; 9.0 g/dL GFR &lt;50 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Zinc</keyword>
</DOC>